Liminatus Pharma Executes 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance
LIMN sits 22% above its 52-week low of $0.095 on light trading volume (0.1× avg).
Summary
Liminatus Pharma is executing a 1-for-50 reverse stock split effective August 20, 2026, to regain compliance with Nasdaq's minimum bid price rule and avoid delisting.
Key Events · Corporate Governance and Compliance · LIMN
-
Reverse Stock Split Executed
Board approved a 1-for-50 reverse stock split on August 3, 2026, and the certificate of amendment was filed on August 18, 2026. The split becomes effective at 4:01 p.m. ET on August 20, 2026.
-
Share Count Reduction
Outstanding shares will be reduced from 67,160,362 to approximately 1,343,208, a 98% reduction. No fractional shares will be issued; fractional interests will be rounded up.
-
Nasdaq Compliance Deadline
The company must demonstrate a $1.00 closing bid price for at least ten consecutive trading days by September 3, 2026, to maintain its Nasdaq Capital Market listing.
-
Trading on Split-Adjusted Basis
Common stock is expected to begin trading on a split-adjusted basis on August 21, 2026, under the existing symbol 'LIMN' with new CUSIP 53271X 207.
Analysis · LIMN · Life Sciences
Liminatus Pharma has filed the certificate of amendment to effect a 1-for-50 reverse stock split, reducing outstanding shares from 67.2 million to approximately 1.34 million. The split is designed to lift the stock price above the $1.00 minimum bid requirement and maintain Nasdaq listing. The company faces a September 3, 2026 deadline to demonstrate compliance, and this action is a critical step to avoid delisting.
At the time of this filing, LIMN was trading at $0.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.10 to $4.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.